High-dose chemotherapy with autologous hematopoietic cell transplantation (AutoHCT) has demonstrated both improvement in event-free survival and overall survival (OS) in patients with multiple myeloma (MM). 1 Despite improved outcomes with novel therapies and AutoHCT, neither strategy provides prolonged disease control in MM. Only allogeneic HCT (AlloHCT), in part due to a graft versus myeloma effect, can provide a potentially curative option. 2 However, the use of AlloHCT has been limited by its toxicity and treatment-related mortality. Historically, AlloHCT was used in patients with aggressive myeloablative conditioning regimens with treatment-related mortality between 15% and 40%. 3 In more recent years, improvements in supportive care and new conditioning regimens have improved these numbers. 4 Rapid immune reconstitution as evidenced by lymphocyte and monocyte recovery has been associated with improved survival in patients after AlloHCT in hematological malignancies, such as acute leukemia. 5 In this study, we sought to find out whether lymphocyte and monocyte recovery are similarly associated with OS in patients undergoing AlloHCT in MM.
We performed an Institutional Review Board-approved retrospective analysis of consecutive patients who underwent AlloHCT for MM between 2002 and 2013 at a tertiary medical center. Patients received either a myeloablative or non-myeloablative conditioning regimen. The non-myeloablative regimen consisted of low dose TBI either alone or with other drugs, fludarabine (Flu) with cyclophosphamide (CyFlu) or TBI with fludarabine (FluTBI) or combination of melphalan with fludarabine (FluMel). Cyclophosphamide with TBI (CyTBI) was the myeloablative conditioning regimen used. All patients underwent prior AutoHCT except for one who had an upfront AlloHCT. GVHD prophylaxis consisted of methotrexate and tacrolimus. Patient received antimicrobial prophylaxis with ciprofloxacin, acyclovir, fluconazole/voriconzaole and trimethoprim-sulfamethaxozole/dapsone.
The primary end point of the study was OS, and we assessed the effect of peripheral blood lymphocyte and monocyte count recovery at day +100 on OS. Two patients died before day 100 and were excluded from the analysis, that is, this was a day 100 landmark analysis. The absolute lymphocyte count (ALC) and absolute monocyte count (AMC) were obtained from a complete blood count carried out at +15, +30, +60 and +100 days after transplant. For survival analyses, a 100-day ALC cutoff of 500 × 10 6 cells/L and AMC cutoff of 300 × 10 6 cells/L was used. Overall survival was assessed from the time of transplantation to last follow-up or death owing to any cause. OS estimates were obtained using the Kaplan-Meier estimator. Development of acute and chronic GVHD and relapse were treated as timedependent co-variates. Cox proportional hazards model was used for univariate and multivariable analyses. Multivariable analysis was carried out with forward stepwise model selection approach to identify significant risk factors. Each step of model building contained the main effect: day-100 ALC and AMC. All analysis were performed in SAS 9.3 (SAS Institute, Cary, NC, USA).
Seventy-eight patients underwent AlloHCT for MM at our institution between 2002 and 2013. Patient, disease and transplant characteristics are shown in Table 1 . The median age at transplant was 53 years (range 23-69), with 64% male predominance. At the time of AlloHCT, 32% of patients had achieved very good partial response or better and the majority had at least a partial response. The related and unrelated donors were 70 (90%) and 8 (10%), respectively. The majority received non-myeloabalative conditioning regimens. The median follow-up was 49.4 months (2.3-129.3).
Very early ALC and AMC recovery at days +15 and +30 were not associated with improved OS on unadjusted analysis. However, by day +60, AMC4300 × 10 6 was strongly associated with decreased risk of dying (hazard ratio (HR) 0.47, 95% confidence interval (CI) 0.28-0.8, P = 0.0002). Day +60 recovery of ALC 4500 × 10 6 was not associated with better survival. On univariate analysis, achievement of ALC4500 × 10 6 and AMC4300 × 10 6 at day +100 were associated with improved survival (HR 0.47, 95% CI 0.28-0.8, P = 0.02 and HR 0.42, 95% CI 0.24-0.74, P = 0.001, respectively). Figures 1a and b show the Kaplan-Meier curves for OS (landmark analysis) of the groups with ⩾ 500 vs o 500 ALC and ⩾ 300 vs o300 AMC day 100 count recovery. The 5-year survival was 75% (95% CI 54.4-87.7) and 27.3% (95% CI 11.3-46.1) for the high day-100 AMC and low day-100 AMC groups, respectively. Other variables associated with OS in unadjusted analysis included age at transplant, disease status at transplant, type of conditioning regimen, number of CD34+ cells infused and relapse or progression of MM after transplant. These factors were then tested in the multivariable models in addition to having AMC and ALC recovery as the main effects. Only two factors were associated with survival on multivariate analysis. Patients with a day-100 AMC count of o 300 had increased mortality with an adjusted HR of 4.5 (95% CI 1.7-12.0, P-value 0.003). Additionally, increasing age at transplant was also associated with higher mortality (for 1 year increase in age, HR 1.05, 95% CI 1.01-1.10, P-value 0.01). Chronic GVHD did not have an effect on survival in either the univariate or multivariable analyses in our study. One year post-transplant mortality was 18%. The cumulative incidence of chronic GVHD was 28.8% (95% CI 20.2-41) and 33.4% (95% CI 24.2-46.1) at 1 and 3 years, respectively.
Rapid post-AlloHCT immune reconstitution is shown to be essential for long-term survival in acute leukemia. 5 Both lymphocyte and monocyte recovery have been shown to have prognostic significance in acute leukemia. 6 Monocytopenia has previously been associated with the development of invasive fungal infections between 40 and 100 days post AlloHCT, although it did not achieve significance on multivariable testing. 7 Consequently, severe monocytopenia o 100 × 10 6 /dL is associated with reduced survival after diagnosis of invasive fungal infections after allogeneic stem cell transplant. 8 In a cohort of patients mainly with acute leukemia and myelodysplastic syndrome, monocyte recovery of 4300 × 10 6 was associated with improved survival after allogeneic stem cell transplant in both myeloablative and reduced intensity conditioning. 5, 6 Similar to these studies, the advantage of our findings is that this information can be easily derived from complete blood count used in routine clinical practice; however, our analysis is limited by the inability to determine the phenotypic and functional changes within the lymphocyte and monocyte populations that may be responsible for this effect seen on survival. Previous studies have shown the deleterious effect of monocyte recovery in patients after AutoHCT in lymphoma. 9 This could be due to the fact that immunological tolerance is not required for autologous graft versus disease effect. 5 Though the exact mechanism remains unclear, monocytes are known to promote tumorigenesis and angiogenesis and suppress the host immune response to cancer. 10 This explains the negative prognostic effect of elevated monocyte counts on solid tumors, such as gastric cancer, head and neck cancer and hepatocellular carcinoma. 11 Monocytes in the circulation are an important source of soluble mediators, which may help support the evolution of malignant cells. 12 However, in another study, recovery of natural killer cells and certain subsets of monocyte cells (CD14+ and not CD16+) were shown to have longer PFS in patients with MM after AutoHCT. 13 Animal models have shown that transplanted bone marrow-derived cells particularly F4/80 + Gr1 + (inflammatory monocytes) and F480
+ Gr1
− (resident monocytes) contribute to mucosal regeneration after bone transplantation resulting in the favorable outcomes.
14 Recent studies have demonstrated that monocytes may contribute to wound healing from vascular injury, spinal cord injury and myocardial infarction. 15 Monocytes are responsible to lead inflammatory cascade and secrete inductive cytokines responsible for revascularization and tissues regeneration at the injury sites. Whether such mechanism is responsible for favorable outcomes after AlloHCT in humans is purely speculative and warrants further investigation.
14 Monocytopenia could be due to various reasons one of which is poor graft function. Chimerism studies and subset analysis of white cell recovery at day 100 may have helped in further delineating graft function further in our study.
In conclusion, we show that monocyte reconstitution is associated with superior survival after AlloHCT in MM and could be used as a prognostic marker for outcomes. Lymphocyte recovery was not found to be similarly prognostic on multivariate analysis. Whether strategies to help improve AMC counts in patients with poor AMC recovery by days 60-100 will result in improved outcomes is unclear but would be worth further study in a larger clinical context.
